Nivolumab + ipilimumab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Sep 2019: Trial registered, NCT04080804
  2. 20 Dec 2019: Trial started, NCT04080804

The trials

NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

State
Under way
Phase
Phase 2
People
80 taking part
Started
20 Dec 2019
Primary completion
13 Apr 2026
Arms
Nivolumab + Ipilimumab
Results
None posted
  1. 6 Sep 2019: Trial registered
  2. 20 Dec 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.